Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Gamida Cell

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Non-Hodgkin Lymphoma

Treatments: Drug: GDA-201

Study type: Interventional

Funder types: Industry

Identifiers

NCT05296525

GC P#01.01.050

Details and patient eligibility

About

This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).

Full description

The study is divided into a phase I dose escalation phase and a phase II expansion phase.

Patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL) will receive GDA-201 followed by a short course of low-dose interleukin-2 (IL-2). Rituximab will be administered prior to and after GDA-201 infusion.

Phase I: Dose escalation phase The objective of Phase I is to evaluate the safety of GDA-201 in patients with FL, DLBCL/ HGBCL, marginal zone lymphoma or mantle cell lymphoma. The maximal tolerated dose (MTD) and recommended Phase II Dose (RP2D) will be determined based on dose limiting toxicities (DLT).

Phase II expansion phase The objective of the Phase II expansion cohort is to evaluate the safety and efficacy of GDA-201 in two patient cohorts, FL and DLBCL/HGBCL.

Enrollment: 13 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients must have relapsed/refractory FL or HGBCL/DLBCL that has failed conventional therapy defined as follows:

   1. Received at least 2 prior lines of therapy
   2. Transplant ineligible patients allowed assuming they meet criterion a.
   3. Patients who received prior chimeric antigen receptor modified T-cells (CAR-T) cell therapy or are considered ineligible for CAR-T therapy per the investigator's discretion
   4. FL transformed to HGBCL: Must have received at least 1 line of therapy after transformation to DLBCL/HGBCL

2. Patients must be at least 18 years of age

3. Patients must have adequate hematologic, hepatic, renal, cardiac and pulmonary function prior to any study treatment.

Exclusion criteria

1. Central Nervous System (CNS) lymphoma

2. Time between previous treatment and first dose of study treatment (rituximab):

   1. Allogeneic hematopoietic stem cell transplantation (HSCT) < 6 months prior to study treatment
   2. Autologous HSCT < 3 months prior to study treatment
   3. CAR-T < 2 months prior to study treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

13 participants in 2 patient groups

GDA-201 Cohort 1 (Phase I)

Other group

Description:

Dose escalation with up to 4 dose levels to reach MTD and determine recommended Phase II dose (RP2D).

Treatment:

Drug: GDA-201

GDA-201 Cohort 2 (Phase II)

Other group

Description:

RP2D will be administered to all patients.

Treatment:

Drug: GDA-201